Profile picture

Doctor Juan Cosin Sales

HOSPITAL ARNAU DE VILANOVA, Valencia (Spain)
Membership: FESC Member
Follow
Logo ESC

Contributor content

Real vs perceived LDL cholesterol control in clinical practice in Spain: Which factors are related to real control?
Presentation
Real vs perceived LDL cholesterol control in clinical practice in Spain: Which factors are related to real control?
Read more
Management of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF) who are older and frail, with moderate renal impairment and multiple comorbidities.
Presentation
Management of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF) who are older and frail, with moderate renal impairment and multiple comorbidities.
Read more
Management of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF) who are older and frail, with moderate renal impairment and multiple comorbidities.
Presentation
Management of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF) who are older and frail, with moderate renal impairment and multiple comorbidities.
Read more
Management of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF) who are older and frail, with moderate renal impairment and multiple comorbidities.
Presentation
Management of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF) who are older and frail, with moderate renal impairment and multiple comorbidities.
Read more
An observational, international, cohort study to evaluate the satisfaction and preferences of patients in preventive treatment of secondary cardiovascular events with a cardiovascular polypill
Presentation
An observational, international, cohort study to evaluate the satisfaction and preferences of patients in preventive treatment of secondary cardiovascular events with a cardiovascular polypill
Read more

ESC 365 is supported by

novartis Explore sponsored resources